Literature DB >> 7681033

Sensitivity and specificity of Gold types 1 to 5 anti-carcinoembryonic antigen monoclonal antibodies: immunohistologic characterization in colorectal cancer and normal tissues.

J M Esteban1, R Paxton, P Mehta, H Battifora, J E Shively.   

Abstract

Carcinoembryonic antigen (CEA) is one of the better-studied oncodevelopmental antigens to which numerous monoclonal antibodies (MoAbs) have been generated. Many of these MoAbs have been recently grouped (Gold classification) according to their epitope recognition. The present study was designed to immunocharacterize various MoAbs, each representative of the five Gold groups, on colorectal cancers and normal tissues using semiquantitative immunohistochemistry. Sensitivity, based on the number of colorectal cancer cases (n = 100) with positive reaction (> 5% cells), was greater with Gold groups 1 and 2 (93% each) than with groups 3, 4, and 5 (78%, 83%, and 87%, respectively). The intensity of the strain also correlated with the Gold groups, with 24%, 20%, and 18% of cancer cases displaying weak or negative staining (0 or 1+) when reacted with MoAbs from groups 3, 4, and 5, respectively, versus 6% and 12% with Gold 1 and 2 antibodies. Cross-reactivity of the anti-CEA antibodies with CEA-related molecules was found to be significant with Gold 5 antibody, which stained most of the normal lung, liver, stomach, and intestinal tissues tested. Strong staining also was seen in granulocytes when they were reacted with Gold 4 and 5 antibodies. The other antibodies showed much less and variable cross-reactivity with normal tissues, with a not statistically significant advantage for Gold 1 antibodies. In addition to lower sensitivity in CEA detection, Gold 3 to 5 MoAbs were less specific due to cross-reaction with one or more of the CEA-related macromolecules expressed by normal tissues. Based on these results and given the broad clinical applications of anti-CEA MoAbs, it is essential to characterize each MoAb to be used for clinical purposes in order to avoid interpretation errors of potential relevance resulting from poor sensitivity/specificity. The use of antibodies that recognize the epitope of group 1 or 2 is recommended to maximize sensitivity and specificity for CEA detection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681033     DOI: 10.1016/0046-8177(93)90044-h

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves.

Authors:  C Vaquero; M Sack; J Chandler; J Drossard; F Schuster; M Monecke; S Schillberg; R Fischer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Spectrum of carcinoembryonic antigen immunoreactivity from isolated ductal hyperplasias to atypical hyperplasias associated with infiltrating ductal breast cancer.

Authors:  F C Schmitt; L Andrade
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

3.  Large-cell neuroendocrine carcinoma without immunohistological positivity or serum elevation of CEA until relapse.

Authors:  Yasutaka Watanabe; Shunsuke Endo; Hiroyoshi Tsubochi; Mitsuhiro Nokubi; Shinichiro Koyama; Yasunori Sohara
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-11-12

4.  Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.

Authors:  Jan Terje Andersen; Stian Foss; Vania E Kenanova; Tove Olafsen; Ingvild S Leikfoss; Derry C Roopenian; Anna M Wu; Inger Sandlie
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

5.  Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up.

Authors:  F A Mauri; O Caffo; S Veronese; P Verderio; P Boracchi; M Bonzanini; N Rossi; G Perrone; P Dalla Palma; M Barbareschi
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

6.  Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation.

Authors:  Maciej Kujawski; Mark Sherman; Susanta Hui; Darren Zuro; Wen-Hui Lee; Paul Yazaki; Anakim Sherman; Barbara Szpikowska; Junie Chea; Desiree Lasiewski; Kofi Poku; Harry Li; David Colcher; Jeffrey Wong; John E Shively
Journal:  Oncoimmunology       Date:  2020-02-14       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.